Roche today gave a presentation debuting its first continuous glucose monitor (CGM) offering that utilizes predictive AI.
The company unveiled its Accu-Chek SmartGuide in an event at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy. It remains an investigational device not yet authorized for sale.
Julien Boisdron, Roche Diabetes Care’s chief medical officer, called it “a solution more than a CGM” during the event. He explained that, comprised of a sensor and two applications, the offering helps visualize data and make predictions as well.
Jochen Berchtold, VP and franchise lead for insulin therapy solutions at Roche Diabetes, highlighted the power of that combination.
“We think that the combination of the strength of a CGM, plus the power of prediction, has the possibility and the potential to change the way how diabetes is managed in the future, by empowering people to take proactive actions and the depth the therapy before a problem,” he said.
Get the full story at our sister site, Drug Delivery Business News.